Lessons from an outbreak of metallo-β-lactamase-producing Klebsiella oxytoca in an intensive care unit: The importance of time at risk and combination therapy

Journal of Hospital Infection

Volumn 89, Issue 2, 2015, Pages 123-131

  Vergara Lopez S ^a   Dominguez M C ^a   Conejo, M C ^b   Pascual, Á ^b,c   Rodriguez Bano J ^b,c  

^a Hospital La Merced   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Carbapenem resistant Enterobacteriaceae; Klebsiella oxytoca; Outbreak; Time at risk

Indexed keywords

AMIKACIN; AMINOPENICILLIN; BETA LACTAMASE; BETA LACTAMASE IMP 8; BETA LACTAMASE OXY 2; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COLISTIN; ERTAPENEM; FOSFOMYCIN; GLYCOPEPTIDE; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; TIGECYCLINE; UNCLASSIFIED DRUG; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CASE CONTROL STUDY; CATHETER INFECTION; CLINICAL FEATURE; CONTROLLED STUDY; EPIDEMIC; FEMALE; HOSPITAL; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA INFECTION; KLEBSIELLA OXYTOCA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANT KLEBSIELLA OXYTOCA; MULTIDRUG RESISTANT KLEBSIELLA OXYTOCA INFECTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RESERVOIR; RISK FACTOR; SPAIN; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; BETA-LACTAM RESISTANCE; BIOSYNTHESIS; CASE-CONTROL STUDIES; CROSS INFECTION; DRUG THERAPY, COMBINATION; ENZYMOLOGY; EPIDEMIOLOGY; HUMANS; INTENSIVE CARE UNITS; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTIONS; MICROBIOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; STATISTICS AND NUMERICAL DATA; TIME FACTORS;

AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CASE-CONTROL STUDIES; CROSS INFECTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTENSIVE CARE UNITS; KLEBSIELLA INFECTIONS; KLEBSIELLA OXYTOCA; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SPAIN; TIME FACTORS;

EID: 84921544058     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2013.12.008     Document Type: Article

References (37)

1. Nordmann P., Naas T., Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011, 17:1791-1798.
2. Magiorakos A.P., Srinivasan A., Carey R.B., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18:268-281.
3. Conejo M.C., Domínguez M.C., López-Cerero L., Serrano L., Rodríguez-Baño J., Pascual A. Isolation of multidrug-resistant Klebsiella oxytoca carrying blaIMP-8, associated with OXY hyperproduction, in the intensive care unit of a community hospital in Spain. JAntimicrob Chemother 2010, 65:1071-1073.
4. Ambler R.P. The structure of beta-lactamases. Phil Trans R Soc Lond B Biol Sci 1980, 289:321-331.
5. Rasmussen B.A., Bush K. Carbapenem-hydrolyzing beta-lactamases. Antimicrob Agents Chemother 1997, 41:223-232.
6. Arakawa Y., Ohta M., Kido N., et al. Chromosomal beta-lactamase of Klebsiella oxytoca, a new class A enzyme that hydrolyzes broad-spectrum beta-lactam antibiotics. Antimicrob Agents Chemother 1989, 33:63-70.
7. Chitnis A.S., Caruthers P.S., Rao A.K., et al. Outbreak of carbapenem-resistant Enterobacteriaceae at a long-term acute care hospital: sustained reductions in transmission through active surveillance and targeted interventions. Infect Control Hosp Epidemiol 2012, 33:984-992.
8. Patel G., Huprikar S., Factor S.H., Jenkins S.G., Calfee D.P. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008, 29:1099-1106.
9. Schwaber M.J., Klarfeld-Lidji S., Navon-Venezia S., Schwartz D., Leavitt A., Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008, 52:1028-1033.
10. Mouloudi E., Protonotariou E., Zagorianou A., et al. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K.pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol 2010, 31:1250-1256.
11. Gasink L.B., Edelstein P.H., Lautenbach E., Synnestvedt M., Fishman N.O. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K.pneumoniae. Infect Control Hosp Epidemiol 2009, 30:1180-1185.
12. Debby B.D., Ganor O., Yasmin M., et al. Epidemiology of carbapenem resistant Klebsiella pneumoniae colonization in an intensive care unit. Eur J Clin Microbiol Infect Dis 2012, 31:1811-1817.
13. Wu D., Cai J., Liu J. Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae. South Med J 2011, 104:106-110.
14. Paterson D.L. Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin Infect Dis 2002, 34:1564-1567.
15. Marchaim D., Chopra T., Bhargava A., et al. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. Infect Control Hosp Epidemiol 2012, 33:817-830.
16. Ben-David D., Kordevani R., Keller N., et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 2012, 18:54-60.
17. Falagas M.E., Rafailidis P.I., Kofteridis D., et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. JAntimicrob Chemother 2007, 60:1124-1130.
18. Falagas M.E., Karageorgopoulos D.E., Nordmann P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol 2011, 6:653-666.
19. Qureshi Z.A., Paterson D.L., Potoski B.A., et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012, 56:2108-2113.
20. Tumbarello M., Viale P., Viscoli C., et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K.pneumoniae: importance of combination therapy. Clin Infect Dis 2012, 55:943-950.
21. Vergara-López S., Domínguez M.C., Conejo M.C., Pascual A., Rodríguez-Baño J. Wastewater drainage system as an occult reservoir in a protracted clonal outbreak due to metallo-β-lactamase-producing Klebsiella oxytoca. Clin Microbiol Infect 2013, 19:490-498.
22. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., Hughes J.M. CDC definitions for nosocomial infections. Am J Infect Control 1988, 16:128-140.
23. McCabe W.R., Jackson G.G. Gram-negative bacteremia. I. Etiology and ecology. Archs Intern Med 1962, 110:847-864.
24. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
25. Hussein K., Sprecher H., Mashiach T., Oren I., Kassis I., Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009, 30:666-671.
26. Bonten M.J., Slaughter S., Ambergen A.W., et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable. Archs Intern Med 1998, 158:1127-1132.
27. Merrer J., Santoli F., Appere de Vecchi C., Tran B., De Jonghe B., Outin H. "Colonization pressure" and risk of acquisition of methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol 2000, 21:718-723.
28. Kritsotakis E.I., Tsioutis C., Roumbelaki M., Christidou A., Gikas A. Antibiotic use and the risk of carbapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study. JAntimicrob Chemother 2011, 66:1383-1391.
29. Lipsitch M., Samore M.H. Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis 2002, 8:347-354.
30. Borer A., Eskira S., Nativ R., et al. Amultifaceted intervention strategy for eradication of a hospital-wide outbreak caused by carbapenem-resistant Klebsiella pneumoniae in Southern Israel. Infect Control Hosp Epidemiol 2011, 32:1158-1165.
31. Castanheira M., Sader H.S., Deshpande L.M., Fritsche T.R., Jones R.N. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008, 52:570-573.
32. Zarkotou O., Pournaras S., Tselioti P., et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011, 17:1798-1803.
33. Pagkalis S., Mantadakis E., Mavros M.N., Ammari C., Falagas M.E. Pharmacological considerations for the proper clinical use of aminoglycosides. Drugs 2011, 71:2277-2294.
34. Daikos G.L., Petrikkos P., Psichogiou M., et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009, 53:1868-1873.
35. Michalopoulos A., Virtzili S., Rafailidis P., Chalevelakis G., Damala M., Falagas M.E. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010, 16:184-186.
36. Nilsson A.I., Berg O.G., Aspevall O., Kahlmeter G., Andersson D.I. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 2003, 47:2850-2858.
37. Souli M., Galani I., Boukovalas S., et al. Invitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother 2011, 55:2395-2397.